[13] Treatment was given for 30 weeks
The cardiovascular protection offered by GLP-1 receptor agonists stems from several complementary mechanisms: Anti-inflammatory effects through suppression of CRP, TNF-, and other inflammatory markers Substantial weight reduction, particularly with higher doses of newer agents Blood pressure modulation via direct vascular effects and enhanced natriuresis Improved endothelial function and lipid profiles Renal protective effects, including reduced albuminuria and slowed eGFR decline Though initially established in type 2 diabetes populations, recent evidence from the SELECT trial confirms these benefits extend to non-diabetic patients with obesity and established cardiovascular disease
Glucagon receptor activation: Increases hepatic glucose output (relevant in fasted states), stimulates lipolysis in adipose tissue, and raises basal metabolic rate through thermogenic mechanisms
What Is Pernicious Anemia and Why Does It Require Injections
#NovoNordisk #Rybelsus #Semaglutide #GLP1 #CardiovascularHealth #Type2Diabetes #MetabolicHealth #FDAApproval FDA Approves Novo Nordisks Rybelsus for Cardiovascular Risk Reduction in Type 2 Diabetes The U.S
However, more serious side effects, such as pancreatitis or kidney problems, can occur in rare cases